RxDoctor Payments Data

Craig Nobert, MD

Urology · New York, NYNPI 1639198294

Payments from drug & device makers

$9,147in general payments, 2019–2025

Across 148 payments — averaging $61.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Boston Scientific$2K
  • Intuitive Surgical$2K
  • Myovant Sciences Inc.$387
  • Teleflex LLC$386
  • Olympus America Inc.$375
  • plus $2K from 19 others

What the payments were for

  • Travel & lodging$3,91143%
  • Food & beverage$5,13756%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,147 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$214,858
Medicare patients
436
Services billed
1,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron127$82,536
GemtesaVibegron74$38,041
Tamsulosin Hcl622$7,986
Oxybutynin Chloride ErOxybutynin Chloride254$4,517
Tadalafil24$3,972
Finasteride238$3,078
Methenamine Hippurate22$1,747
Desmopressin Acetate36$1,555
Silodosin23$1,452
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst73$1,224
Estradiol12$763
Alfuzosin Hcl ErAlfuzosin Hcl44$733
Sildenafil Citrate25$653
Oxybutynin Chloride60$554
Dutasteride15$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$365$82,536127 claims
Sumitomo Pharma America, Inc.Gemtesa$56$38,04174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →